<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03329885</url>
  </required_header>
  <id_info>
    <org_study_id>IM024-005</org_study_id>
    <secondary_id>2017-003408-38</secondary_id>
    <nct_id>NCT03329885</nct_id>
  </id_info>
  <brief_title>A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Patients and Patients With Average to Very Serious Psoriasis</brief_title>
  <official_title>A Double-Blind Randomized Placebo-Controlled Single and Multiple Ascending Doses Study of the Safety and Tolerability, Pharmacokinetics (Including Bioavailability Comparison and Food Effect) and Pharmacodynamics of Oral BMS-986251 Administration in Healthy Subjects, With Efficacy Assessment of Multiple Doses in Patients With Moderate-to-Severe Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate experimental medication BMS-986251 taken by mouth
      in healthy patients and patients with average to very serious Psoriasis (a condition
      characterized by itchy, dry skin with a scaly rash).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2017</start_date>
  <completion_date type="Anticipated">August 17, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Serious Adverse Events (SAE)</measure>
    <time_frame>Up to 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Adverse Events (AE) leading to study discontinuation</measure>
    <time_frame>Up to 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of deaths</measure>
    <time_frame>Up to 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of potentially clinically significant changes in electrocardiogram (ECG) parameters</measure>
    <time_frame>Up to 14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of potentially clinically significant changes in vital signs</measure>
    <time_frame>Up to 14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of potentially clinically significant changes in clinical laboratory parameters</measure>
    <time_frame>Up to 14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of maximum observed plasma concentration (tmax)</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-t)]</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(0-inf)]</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination half-life, calculated as 0.693/kel [t(1/2)]</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent (oral) clearance (CL/F)</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution at terminal phase [V(z)/F]</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative urinary excretion [Ae(t)]</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount excreted unchanged in urine (% of dose) [Fe(urine)%]</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal clearance [CL(R)]</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve over 24 hours (one dosing interval) [AUC(0-24)]</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of AUC(0-24) following last dose to AUC(0-24) following first dose [AR[AUC(0-24)]]</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of Cmax following last dose to Cmax following first dose [AR(Cmax)]</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pre-dose plasma concentration (Cpre)</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed inhibition [I(max)]</measure>
    <time_frame>Up to 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed inhibition [t(Imax)]</measure>
    <time_frame>Up to 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of inhibition above 50% [t(I&gt;50%)]</measure>
    <time_frame>Up to 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of inhibition above 90% [t(I&gt;90%)]</measure>
    <time_frame>Up to 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose inhibition [I(pre)]</measure>
    <time_frame>Up to 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inhibition at time t [I(t)]</measure>
    <time_frame>Up to 2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">192</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Psoriasis</condition>
  <condition>Ankylosing Spondylitis</condition>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Part A Single Ascending Dose (SAD) in Healthy Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy patient will receive single escalating oral doses of BMS-986251 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Multiple Ascending Dose (MAD) in Healthy Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy patients will receive daily escalating oral doses of BMS-986251 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C Multiple Dosing in Psoriasis Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Psoriasis patients will receive daily escalating oral doses of BMS-986251 or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986251</intervention_name>
    <description>Escalating oral dose</description>
    <arm_group_label>Part A Single Ascending Dose (SAD) in Healthy Patients</arm_group_label>
    <arm_group_label>Part B Multiple Ascending Dose (MAD) in Healthy Patients</arm_group_label>
    <arm_group_label>Part C Multiple Dosing in Psoriasis Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Escalating oral dose</description>
    <arm_group_label>Part A Single Ascending Dose (SAD) in Healthy Patients</arm_group_label>
    <arm_group_label>Part B Multiple Ascending Dose (MAD) in Healthy Patients</arm_group_label>
    <arm_group_label>Part C Multiple Dosing in Psoriasis Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria (Healthy Patients):

          -  Males and females, ages 18 to 55 years, inclusive, at screening

          -  Healthy subjects, as determined by no clinically significant deviations from normal in
             medical history, physical examination, 12-lead ECGs, vital signs, and clinical
             laboratory results

          -  Body mass index (BMI) of 18.0 to 30.0 kg/m2, inclusive, at screening

          -  Body weight between 55 kg and 105 kg, inclusive, at screening

          -  Women must not be breastfeeding

        Exclusion Criteria (Healthy Patients):

          -  Previous participation in the current study

          -  Participation in a drug study or exposure to any investigational drug or placebo
             within 2 months prior to (the first) drug administration in the current study

          -  Employees of PRA or the Sponsor and their relatives

          -  Any significant acute or chronic medical condition that presents a potential risk to
             the subject and/or that may compromise the objectives of the study, including active,
             or history of, liver disease, or intestinal disorder including irritable bowel
             syndrome

          -  Current or recent (within 3 months of study treatment administration) gastrointestinal
             disease that could affect pharmacokinetics; history of cholecystectomy is not allowed

        Inclusion Criteria (Psoriasis Patients):

          -  Males and females, ages 18 to 70 years, inclusive, at screening

          -  BMI of 18.0 to 35.0 kg/m2, inclusive, at screening

          -  Body weight between 55 kg and 120 kg, inclusive, at screening

          -  Diagnosed with stable chronic plaque psoriasis, for at least 6 months prior to
             screening and be candidates for either photo-therapy or systemic treatment

          -  Moderate-to-severe intensity of psoriasis as defined by:

               1. Affected body surface area (BSA) of ≥10%

               2. Psoriasis Area and Severity Index (PASI) ≥12

               3. Physician Global Assessment (PGA; 6-point scale) ≥3

        Exclusion Criteria (Psoriasis Patients):

          -  Previous participation in the current study

          -  Participation in a drug study or exposure to any investigational drug or placebo
             within 2 months prior to (the first) drug administration in the current study

          -  Employees of PRA or the Sponsor and their relatives

          -  Any significant acute or chronic medical condition that presents a potential risk to
             the subject and/or that may compromise the objectives of the study, including active,
             or history of, liver disease, or intestinal disorder including irritable bowel
             syndrome

          -  Current or recent (within 3 months of study treatment administration) gastrointestinal
             disease that could affect pharmacokinetics; history of cholecystectomy is not allowed

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Groningen</city>
        <zip>9728 NZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2017</study_first_submitted>
  <study_first_submitted_qc>October 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

